values for RVC and FVC were not different. The number of patients showing a greater than 330 ml overall improvement in RVC was 20 of 27 for sequence 1 and 22 of 27 for sequence 2; similar trends were observed for FEV, and FVC. For all three parameters there was a significant difference between mean responses to low and high doses of terbutaline when the latter was given as the first drug in sequence 1. When ipratropium was given first in sequence 2 there was, however, no significant improvement with high dose terbutaline over and above the response to low dose terbutaline. The latter effect was more noticeable with RVC than with either FEVy or FVC. The total bronchodilator response at the end of each sequence was similar whether ipratropium was given first or second. Conclusions-The measurement of RVC, FEV1, and FVC were equally effective at picking up those patients who had a significant overall bronchodilator response to combined therapy with inhaled 82 agonist and anticholinergic medication. There was no significant benefit of adding a higher dose of terbutaline when ipratropium bromide had been given previously, particularly when using RVC as the parameter of response.
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There (RVC) lung volumes in assessing bronchodilator response in patients with COPD.
Our study had two specific aims. Firstly, to investigate the bronchodilator response to low and high doses of ipratropium and terbutaline given either alone or in combination. Secondly, to assess whether there were any differences between RVC, FEV1, or FVC in detecting bronchodilator responsiveness.
Methods

PATiENTS
Twenty nine inpatients with COPD were initially recruited into the study. One patient withdrew because of severe tremor following high dose terbutaline and one patient was withdrawn as she was unable to perform pulmonary function tests due to coughing. Twenty seven patients of mean (SE) age 69 (2) years completed the study and were included in the analysis. All patients had recovered following an admission for an acute infective exacerbation of COPD with a mean hospital stay of eight days. All had stable peak flow recordings which had reached a plateau level for at least three days before entry into the study. All patients were studied within 24 hours of discharge from hospital when bronchodilator reversibility testing would normally have been performed. All patients were receiving nebulised salbutamol and oral corticosteroid treatment, with doses remain- 
Sequence1
Mean responses to FEV, showed similar overall trends to RVC. In sequence 1 low J dose terbutaline produced a significant (p < 0 60-> 
